Acute Effects of Intra-Coronary Tirofiban on No-Reflow Phenomena in Patients with ST-Segment Elevated Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention
DOI:
https://doi.org/10.70749/ijbr.v3i7.2747Keywords:
ST-segment Elevation Myocardial Infarction, No-reflow Phenomenon, Tirofiban; Primary Percutaneous Coronary Intervention, TIMI Flow Grade, Intracoronary Administration, Glycoprotein IIb/IIIa Inhibitor.Abstract
Background: No-reflow phenomenon following primary percutaneous coronary intervention in ST-segment elevation myocardial infarction increases mortality risk. Intracoronary tirofiban has shown variable results in previous studies, with success rates ranging from 0% to 96.7%. This study aimed to determine the acute effects of intracoronary tirofiban in patients with persistent no-reflow despite intracoronary nitroglycerine administration. Methods: This quasi-experimental study included 131 patients aged 30-75 years with ST-segment elevation myocardial infarction who developed no-reflow phenomenon (TIMI grade 0) during primary percutaneous coronary intervention at Sheikh Zayed Medical College and Hospital, Rahim Yar Khan, from 25-February to 24-June 2025. Following failed response to intracoronary nitroglycerine, intracoronary tirofiban was administered at 25 μg/kg. Coronary angiography was repeated after ten minutes to assess TIMI flow grade improvement. Data analysis included descriptive statistics and stratified analysis using chi-square test, with statistical significance set at p ≤ 0.05. Results: The mean age was 56.3 ± 10.8 years, with 71.8% male patients. TIMI grade 3 flow was achieved in 82.4% of patients (95% CI: 75.3%-88.2%). Overall improvement in TIMI flow was observed in 87.8% of cases. Statistically significant associations were found between TIMI grade 3 achievement and age groups (p=0.048), body mass index categories (p=0.041), infarction territory (p=0.019), diabetes mellitus (p=0.024), and smoking status (p=0.026). Conclusion: Intracoronary tirofiban demonstrated substantial efficacy in reversing no-reflow phenomenon after failed nitroglycerine therapy, with higher success rates in younger patients, non-diabetic individuals, non-smokers, and those with inferior wall infarction.
Downloads
References
1. Avdikos, G., Michas, G., & Smith, S. W. (2022). From Q/non-Q myocardial infarction to STEMI/NSTEMI: why it’s time to consider another simplified dichotomy; a narrative literature review. Archives of Academic Emergency Medicine, 10(1), e78.
https://doi.org/10.22037/aaem.v10i1.1783
2. Birnbaum, Y., Rankinen, J., Jneid, H., Atar, D., & Nikus, K. (2022). The role of ECG in the diagnosis and risk stratification of acute coronary syndromes: An old but indispensable tool. Current Cardiology Reports, 24(2), 109-118.
https://doi.org/10.1007/s11886-021-01628-7
3. Khalid, S. H., Liaqat, I., Mallhi, T. H., Khan, A. H., Ahmad, J., & Khan, Y. H. (2020). Impact of diabetes mellitus on clinico-laboratory characteristics and in-hospital clinical outcomes among patients with myocardial. Journal of the Pakistan Medical Association, 1-20.
https://doi.org/10.47391/jpma.370
4. Baechli, C., Koch, D., Bernet, S., Gut, L., Wagner, U., Mueller, B., Schuetz, P., & Kutz, A. (2020). Association of comorbidities with clinical outcomes in patients after acute myocardial infarction. IJC Heart & Vasculature, 29, 100558.
https://doi.org/10.1016/j.ijcha.2020.100558
5. Akhtar, A., Saleemi, M. S., Zarlish, Q. M., Arshad, M. B., Hashmi, K. A., & Ghafoor, H. (2023). Experience and outcomes of primary percutaneous coronary intervention in a tertiary care hospital in south Punjab, Pakistan. Cureus.
https://doi.org/10.7759/cureus.50024
6. Rao, S., Bhardwaj, R., Negi, P., & Nath, R. K. (2023). No reflow phenomenon in CAD patients after percutaneous coronary intervention: A prospective hospital based observational study. Indian Heart Journal, 75(2), 156-159.
https://doi.org/10.1016/j.ihj.2023.02.002
7. Faruk Akturk I, Arif Yalcin KA, Biyik I, et al.: (2014). Effects of verapamil and adenosine in an adjunct to tirofiban on resolution and prognosis of noreflow phenomenon in patients with acute myocardial infarction. Minerva Cardioangiol, 62, 389–97.
8. Park, C., Cho, J., Kim, D., & Kim, C. (2016). Intracoronary nitroglycerin injection through a microcatheter for coronary no-reflow following percutaneous coronary intervention. International Journal of Cardiology, 214, 400-402.
https://doi.org/10.1016/j.ijcard.2016.03.127
9. Duan, H., Wan, X., & Li, B. (2017). Effects of intracoronary arterial injection of tirofiban on no-reflow phenomenon in patients with acute ST-segment elevation myocardial infarction underwent primary percutaneous coronary intervention. Discussion of Clinical Cases, 4(2), 1.
https://doi.org/10.14725/dcc.v4n2p1
10. Huang, D., Qian, J., Liu, Z., Xu, Y., Zhao, X., Qiao, Z., Fang, W., Jiang, L., Hu, W., Shen, C., Liang, C., Zhang, Q., & Ge, J. (2021). Effects of Intracoronary pro-urokinase or Tirofiban on coronary flow during primary percutaneous coronary intervention for acute myocardial infarction: A multi-center, placebo-controlled, single-blind, randomized clinical trial. Frontiers in Cardiovascular Medicine, 8.
https://doi.org/10.3389/fcvm.2021.710994
11. Akpek, M., Sahin, O., Sarli, B., Baktir, A. O., Saglam, H., Urkmez, S., Ergin, A., Oguzhan, A., Arinc, H., & Kaya, M. G. (2014). Acute effects of Intracoronary Tirofiban on no-reflow phenomena in patients with ST-segment elevated myocardial infarction undergoing primary percutaneous coronary intervention. Angiology, 66(6), 560-567.
https://doi.org/10.1177/0003319714545780
12. Oikonomou, E., Mourouzis, K., Vogiatzi, G., Siasos, G., Deftereos, S., Papaioannou, S., Latsios, G., Tsalamandris, S., & Tousoulis, D. (2018). Coronary microcirculation and the no-reflow phenomenon. Current Pharmaceutical Design, 24(25), 2934-2942.
https://doi.org/10.2174/1381612824666180911122230
13. Ghonim, A. A., Mostafa, A., Emara, A., Algazzar, A. S., & Qutub, M. A. (2019). Clinical outcome of intracoronary versus intravenous high-dose bolus administration of tirofiban in diabetic patients undergoing primary percutaneous coronary intervention. Cardiovascular Journal of Africa, 30(5), 285-289.
https://doi.org/10.5830/cvja-2019-027
14. Tang, X., Li, R., Jing, Q., Liu, Y., & Liu, P. (2015). Efficacy and safety of Intracoronary versus intravenous administration of Tirofiban during percutaneous coronary intervention for acute coronary syndrome: A meta-analysis of randomized controlled trials. PLOS ONE, 10(6), e0129718.
https://doi.org/10.1371/journal.pone.0129718
15. Tian, R., Liu, R., Zhang, J., Li, Y., Wei, S., Xu, F., Li, X., & Li, C. (2023). Efficacy and safety of intracoronary versus intravenous tirofiban in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: A meta-analysis of randomized controlled trials. Heliyon, 9(5), e15842.
https://doi.org/10.1016/j.heliyon.2023.e15842
16. Jia, H., Lu, C., & Sun, P. (2017). Intracoronary administration of tirofiban during percutaneous coronary intervention facilitates patients with acute coronary syndrome. Oncotarget, 8(63), 107303-107311.
https://doi.org/10.18632/oncotarget.19179
17. Chen, Y., Zhou, P., Yan, H., Zhao, H., Song, L., Liu, C., ... & Wang, J. (2013). Impact of selective infarct-related artery infusion of tirofiban on myocardial reperfusion and bleeding complications in patients with acute myocardial infarction: the SUIT-AMI trial. The Journal of Invasive Cardiology, 25(8), 376-382.
18. Saddique, M. A., Jamshaid, M. M., Abbas, S., & Jabeen, K. (2022). Outcome of Intracoronary Tirofiban administration at primary percutaneous coronary intervention in St-elevation myocardial infarction patients. Pakistan Journal of Cardiovascular Intervention, 2(1), 20-27.
https://doi.org/10.58889/pjcvi.2.20.27
19. Saddique, M. A., Jamshaid, M. M., Abbas, S., & Jabeen, K. (2022). Outcome of Intracoronary Tirofiban administration at primary percutaneous coronary intervention in St-elevation myocardial infarction patients. Pakistan Journal of Cardiovascular Intervention, 2(1), 20-27.
https://doi.org/10.58889/pjcvi.2.20.27
20. Chen, G., Wang, H., Zou, J., & Yuan, X. (2020). Effects of intracoronary injection of nicorandil and tirofiban on myocardial perfusion and short-term prognosis in elderly patients with acute ST-segment elevation myocardial infarction after emergency PCI. World Journal of Emergency Medicine, 11(3), 157.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Indus Journal of Bioscience Research
This work is licensed under a Creative Commons Attribution 4.0 International License.
